NYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-07-23
Reading WRBY? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a stable management team. The current thesis state is intact, supported by robust earnings quality and strong recent performance.
The market currently prices WRBY at an expensive valuation compared to peers, reflecting a durable premium. There is an expectations gap, indicating that investors may not fully believe in the company's ability to sustain its growth trajectory.
Fundamentals are likely to show continued revenue growth, as management aims for a 10% to 12% increase in 2026. However, there is a near-term risk of missing earnings estimates, given the company's recent history of a significant earnings miss.
The thesis hinges on the company's ability to maintain its growth targets and the performance of key sector bellwethers. If these companies continue to perform well, WRBY may benefit from the overall sector momentum.
In the next 1 to 3 years, WRBY's performance will depend on its execution and external market conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. Concerns about leadership commitment have increased due to stock sales. Insider selling by co-CEOs raises doubts about confidence in the company.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: This report will show how much money the company is making and how it is doing.
Confirms one read:Earnings report shows revenue growth meeting or exceeding 10% year over year.
Confirms the other:Earnings report shows revenue growth below 10% year over year.
Why it matters: Meeting this growth target shows Warby Parker is on track with its annual goals. It confirms strong demand and effective strategies.
Confirms:Q2 revenue growth year over year meets or exceeds 10%.
Disproves:Q2 revenue growth year over year falls below 10%.
Why it matters: Progress on the $100M share repurchase program can signal management's confidence in the stock. Delays may raise concerns.
Confirms one read:Announcement of share repurchases totaling $50M or more by Q3 2026.
Confirms the other:No updates or delays in the share repurchase program by Q3 2026.
Why it matters: Opening 50 new stores is important for growth. Delays or fewer openings may show problems.
Confirms:Announcement of 25 or more new store openings by Q3 2026.
Disproves:Fewer than 25 new store openings announced by Q3 2026.
Why it matters: Opening new stores is crucial for growth. It shows Warby Parker's commitment to expanding its market presence.
Confirms:Warby Parker opens at least 50 new stores by the end of 2026.
Disproves:Fewer than 50 new stores opened by the end of 2026.
Why it matters: This launch could attract new customers and boost sales. It represents a key innovation for the brand.
Confirms:A press release will confirm when intelligent eyewear will launch.
Disproves:No announcement or delay in the launch of intelligent eyewear.
Why it matters: A steady gross margin shows good cost control and pricing. This is important for profit.
Confirms:Gross margin reported above 54% in Q2.
Disproves:Gross margin falls below 54% in Q2.
